- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00111735
Thyroxine Titration Study
What is the Optimal Serum TSH Concentration During Thyroxine Treatment for Primary Hypothyroidism? Effects of Fine Titration of Thyroxine Dosage on Wellbeing, Quality of Life and Cognitive Function
Study Overview
Detailed Description
Primary hypothyroidism is a common disorder, affecting 2% of the Australian population. The standard treatment is with thyroxine (T4), and conventionally, a serum thyrotropin (TSH) concentration within the laboratory range is taken as indicating adequacy of thyroxine dosage.
Some patients with hypothyroidism complain of persistently impaired well-being, despite taking thyroxine in a dose which normalises serum TSH concentrations. It is not clear whether this is because of comorbidity or because standard thyroxine replacement is in some way inadequate for some individuals.
The reference range for serum TSH is wide (currently 0.34-4.8 mU/L at PathCentre). The distribution of serum TSH concentrations in the population is skewed, with the mean and median in the lower reference range at approximately 1.0 mU/L. This has led some to argue that a serum TSH in the lower reference range should be the usual therapeutic target. Anecdotal evidence suggests that some thyroxine-treated patients do feel better if the thyroxine dose is adjusted so that serum TSH is in the lower reference range rather than the upper reference range. The National Academy for Clinical Biochemistry of the United States now recommends, that for thyroxine-treated patients, that serum TSH should be less than 2.0 mU/L. There is, however, no evidence from properly conducted studies that aiming for a serum TSH concentration in the lower reference range improves symptoms of hypothyroidism or general wellbeing, and this proposal has not been generally adopted.
Only one study examining the effects of fine titration of thyroxine dosage on wellbeing has been published. In this study, patients had significantly improved wellbeing if they took a dose of thyroxine which was 50 μg greater than their biochemically optimal dose as determined by a thyrotropin-releasing hormone test. In most cases, serum TSH was suppressed to below 0.2 mU/L (the limit of sensitivity of the assay) on the thyroxine doses which improved wellbeing. This study was open-label and non-randomised, and the results therefore may have been affected by bias.
A well-designed, double blind study of the effects of fine titration of thyroxine dosage on symptoms of hypothyroidism, wellbeing and quality of life is required to determine if a serum TSH in the lower reference range, rather than simply TSH within the reference range, should indeed be the usual therapeutic target for thyroxine therapy in primary hypothyroidism. It is also desirable to confirm the findings of Carr et al., that patients have improved wellbeing if TSH is suppressed to below normal levels.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects >18 years of age
- Primary hypothyroidism ≥6 months duration arising from autoimmune hypothyroidism, thyroidectomy or radioiodine treatment
- Thyroxine dose ≥100 mcg/day
- No change in thyroxine dose in past 2 months
- Serum TSH of 0.1-4.8 mU/L
- Adequate contraceptive measures for women of childbearing age
Exclusion Criteria:
- Major systemic illness affecting quality of life or likely to affect participation in the study
- Treatment with T3 currently or in past 2 months
- History of thyroid cancer requiring suppression of TSH secretion by thyroxine
- Ischaemic heart disease - previous myocardial infarction, angina or coronary artery revascularisation
- Renal failure: serum creatinine >135 micromol/L
- Known liver disease with alkaline phosphatase or ALT >2x upper limit of reference range
- Bony fracture in past 3 months or Paget's disease of bone
- Secondary (central) hypothyroidism or hypopituitarism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Visual analog scales assessing wellbeing
|
Secondary Outcome Measures
Outcome Measure |
---|
quality of life scores
|
treatment satisfaction score
|
treatment preference
|
cognitive function tests
|
clinical and biochemical markers of thyroid hormone action
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2003-015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypothyroidism
-
Kerman University of Medical SciencesCompletedPrediction Hypothyroidism Patients Using Machine Learning Algorithms | Identification of Important Symptoms of HypothyroidismIran, Islamic Republic of
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingHypothyroidism; IrradiationItaly
-
Cooperativas Lacteas UnidasGalician South Health Research InstituteNot yet recruitingSubclinical HypothyroidismSpain
-
IBSA Institut Biochimique SACompletedHypothyroidism;PostablativeUnited States
-
Peking Union Medical College HospitalBeijing Municipal Science & Technology CommissionCompletedSubclinical HypothyroidismChina
-
University Hospital DubravaRecruitingHypothyroidism PrimaryCroatia
-
VA Office of Research and DevelopmentCentral Arkansas Veterans Healthcare SystemCompletedSubclinical HypothyroidismUnited States
-
University of Colorado, DenverCharite University, Berlin, GermanyTerminatedHypothyroidism | Postsurgical HypothyroidismUnited States
-
AbbottDimension ResearchCompletedSubclinical HypothyroidismPakistan
Clinical Trials on Thyroxine
-
I.M. Sechenov First Moscow State Medical UniversityCompleted
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRecurrence | Surgery | Thyroid CancerChina
-
Washington University School of MedicineMid-America TransplantCompleted
-
Tokyo Women's Medical UniversityTokyo Metropolitan Bokuto HospitalCompleted
-
Hawler Medical UniversityCompletedPregnancy Loss | Sub Clinical Hypothyroidism
-
Shandong Provincial HospitalUnknownEndocrine System Diseases | Hypothyroidism | Thyroid DiseasesChina
-
Shandong Provincial HospitalActive, not recruitingEndocrine System Diseases | Hypothyroidism | Thyroid DiseasesChina
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Meyer Children's HospitalUnknown
-
NHS Greater Glasgow and ClydeUniversity of Bern; Leiden University Medical Center; University College Cork; University...CompletedSubclinical HypothyroidismUnited Kingdom